Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of TT-00920 in Healthy Subjects
NCT05355129Phase 1Completed
- Sponsor
- TransThera Biosciences
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TT-00920 in heart failure (HF) and heart failure with preserved ejection fraction (HFpEF) (4 arms), sponsored by TransThera Biosciences. Primary endpoints: Treatment-emergent Adverse Events at 20 days, Clinically Relevant Changes in Vital Signs at 20 days and 2 more. Started Nov 2021; status: completed.
02
Drugs
TT-00920
03
Conditions
heart failure (HF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05355129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355129.